NASDAQ:SLGL - Sol Gel Technologies Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$6.98 +0.22 (+3.25 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$6.76
Today's Range$6.76 - $7.01
52-Week Range$6.18 - $16.48
Volume34,806 shs
Average Volume16,259 shs
Market Capitalization$131.89 million
P/E Ratio-1.39
Dividend YieldN/A
BetaN/A
Sol Gel Technologies logoSol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea. It is also involved in the development of generic dermatological drug products. Sol-Gel Technologies Ltd. has collaboration with Perrigo; and Douglas Pharmaceuticals for the development and commercialization of a generic product candidate. The company was founded in 1997 and is headquartered in Ness Ziona, Israel.

Receive SLGL News and Ratings via Email

Sign-up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SLGL
CUSIPN/A
Phone972-8931-3433

Debt

Debt-to-Equity RatioN/A
Current Ratio43.22
Quick Ratio0.16

Price-To-Earnings

Trailing P/E Ratio-1.39
Forward P/E Ratio-3.17
P/E GrowthN/A

Sales & Book Value

Annual Sales$170,000.00
Price / Sales776.83
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees49
Outstanding Shares18,920,000
Market Cap$131.89

The Truth About Cryptocurrencies

Sol Gel Technologies (NASDAQ:SLGL) Frequently Asked Questions

What is Sol Gel Technologies' stock symbol?

Sol Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

How were Sol Gel Technologies' earnings last quarter?

Sol Gel Technologies Ltd (NASDAQ:SLGL) announced its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.06. The business earned $0.04 million during the quarter. View Sol Gel Technologies' Earnings History.

When is Sol Gel Technologies' next earnings date?

Sol Gel Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, August, 21st 2018. View Earnings Estimates for Sol Gel Technologies.

What price target have analysts set for SLGL?

4 analysts have issued 12-month target prices for Sol Gel Technologies' shares. Their forecasts range from $17.00 to $21.00. On average, they expect Sol Gel Technologies' share price to reach $19.00 in the next year. This suggests a possible upside of 172.6% from the stock's current price. View Analyst Ratings for Sol Gel Technologies.

What is the consensus analysts' recommendation for Sol Gel Technologies?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol Gel Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Sol Gel Technologies stock?

Here are some recent quotes from research analysts about Sol Gel Technologies stock:
  • 1. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We have valued Sol-Gel based on a composite assessment of the company’s most advanced clinical-stage drugs. Underlying this, we employ a discounted cash flow (DCF)-based analysis that culminates in a risk-adjusted net present value (rNPV) valuation for each of these agents. This yields a value of $102M for TWIN, assuming a 50% probability of success, and a $323M valuation for VERED, assuming a 60% probability of success. The generic ivermectin cream program contributes a value of $7M to our composite assessment." (7/16/2018)
  • 2. According to Zacks Investment Research, "Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel. " (6/28/2018)

Who are some of Sol Gel Technologies' key competitors?

Who are Sol Gel Technologies' key executives?

Sol Gel Technologies' management team includes the folowing people:
  • Dr. Alon Seri-Levy, Co-Founder & CEO (Age 57)
  • Prof. David Avnir, Co-Founder
  • Mr. Gilad Mamlok, Chief Financial Officer (Age 50)
  • Mr. Itzik Yosef, VP of Operations (Age 42)
  • Ms. Karine Neimann, VP of Projects & Planning and Chief Chemist (Age 47)

When did Sol Gel Technologies IPO?

(SLGL) raised $60 million in an IPO on Thursday, February 1st 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ acted as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

When does Sol Gel Technologies' lock-up period expire?

Sol Gel Technologies' lock-up period expires on Tuesday, July 31st. Sol Gel Technologies had issued 6,250,000 shares in its IPO on February 1st. The total size of the offering was $75,000,000 based on an initial share price of $12.00. After the expiration of Sol Gel Technologies' lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Has Sol Gel Technologies been receiving favorable news coverage?

News coverage about SLGL stock has been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sol Gel Technologies earned a news impact score of 0.07 on Accern's scale. They also gave news headlines about the company an impact score of 44.33 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Sol Gel Technologies?

Shares of SLGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sol Gel Technologies' stock price today?

One share of SLGL stock can currently be purchased for approximately $6.97.

How big of a company is Sol Gel Technologies?

Sol Gel Technologies has a market capitalization of $131.89 million and generates $170,000.00 in revenue each year. The company earns $-31,560,000.00 in net income (profit) each year or ($5.02) on an earnings per share basis. Sol Gel Technologies employs 49 workers across the globe.

How can I contact Sol Gel Technologies?

Sol Gel Technologies' mailing address is 7 GOLDA MEIR ST.WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403650. The company can be reached via phone at 972-8931-3433.


MarketBeat Community Rating for Sol Gel Technologies (NASDAQ SLGL)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  41 (Vote Underperform)
Total Votes:  75
MarketBeat's community ratings are surveys of what our community members think about Sol Gel Technologies and other stocks. Vote "Outperform" if you believe SLGL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLGL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.